1   Quantitative analysis of four rapid antigen assays for detection of pandemic H1N1 2009

2   compared with seasonal H1N1 and H3N2 influenza A viruses on nasopharyngeal aspirates

3   from patients with influenza

4

5   Chan KH[a], Chan KM[b,c], Ho YL[b,c], Lam YP[b,c], Tong HL[b,c], Poon LLM[b,c], Cowling BJ[d] and Peiris JSM[c,d]

6   [a]Department of Microbiology, Queen Mary Hospital, Hong Kong

7   [b]Department of Microbiology, The University of Hong Kong; Hong Kong

8   [c]Centre of Influenza Research, The University of Hong Kong, Hong Kong

9   [d]School of Public Health, The University of Hong Kong, Hong Kong

10

11   Running title: Rapid diagnosis of Influenza A

12

13   Key words: Pandemic H1N1 2009, seasonal H1N1 and H3N2, rapid antigen detection kit, real time

14   quantitative RT-PCR

15

16   Address correspondence: Dr KH Chan, Department of Microbiology, University Pathology Building, Queen

17   Mary Hospital Compound, Pokfulam, Hong Kong

18   E mail: chankh2@hkucc.hku.hk

19   Conflicts of interest: None

20

Abstract

Data on analytical sensitivity of rapid diagnostic assays are important for clinical management of influenza, especially during a pandemic. Four rapid antigen detection assays were compared for detection of pandemic influenza A H1N1 2009, seasonal H1N1 and H3N2 in 96 patients with influenza A infection confirmed by real-time RT-PCR. These rapid antigen tests appeared to have lower sensitivity (55.8%) for the diagnosis of pandemic influenza A H1N1 2009 as compared with seasonal H3N2 (71.0%) or H1N1 (69.4%) influenza infections, a difference that was related to a lower viral load in patients infected with the pandemic influenza A H1N1 2009 virus. The detection limit of these antigen detection tests in clinical specimens was an influenza A M gene copy number of average 1.0×10^{7} copies /ml. Significant variations between tests in sensitivity for detection of pandemic influenza A H1N1 2009 (43.4-63.3%) were observed. The Directigen EZ Influenza A+B and the Espline Influenza A+B had comparable sensitivity (63%) and were the most sensitive among the four assays evaluated.

1.   Introduction

Influenza A virus infection is a common cause of respiratory illness and contributes to morbidity and mortality annually, particularly in young children and in the elderly. Occasionally, animal influenza viruses transmit zoonotically to humans giving rise to severe clinical diseases such as avian H5N1 (de Jong et al., 2006). A novel influenza A (H1N1) 2009 (pH1N1 2009) virus of swine in origin was detected in Mexico and USA in April 2009 [Novel swine-origin influenza A (H1N1) virus investigation team, 2009]. The virus was efficient at transmitting from human to human and spread globally to cause a pandemic (Fraser et al., 2009). Rapid, simple and reliable diagnostic tests for confirming infection with influenza A can improve clinical management by guiding the appropriate use of antivirals and antibiotics. It has been previously demonstrated that the analytical sensitivity of many of these influenza A antigen detection tests for detection of avian H5N1 and pH1N1 2009 was comparable with that of seasonal influenza A infected cell lysates (Chan et al., 2007 and 2009). Recently, several studies reported that these rapid kits had clinical diagnostic sensitivity ranging from 10-80% for detection of pH1N1 2009 (Cowling et al., 2010; Ginocchio et al., 2009; Gordon et al., 2010; Kumar et al., 2010, Yang et al., 2011). However, the reasons for this variable and poor sensitivity of rapid antigen assays for clinical samples with pH1N1 2009 have not been investigated. The present study is to correlate clinical diagnostic sensitivity of four commercially available rapid antigen detection tests to viral load in the clinical specimens as determined by quantitative PCR methods in patients infected with seasonal H1N1 (sH1N1), seasonal H3N2 (sH3N2) and pH1N1 2009 influenza A. The performance of these rapid kits was also compared with direct immunofluorescence antigen detection kit and conventional virus culture.

2.   Materials and Methods

2.1   Clinical samples

Ninety seven nasopharyngeal aspirate specimens collected from hospitalized patients with suspected influenza from July 2009 to January 2010 sent to the virology laboratory at the Queen Mary Hospital, Hong Kong for routine diagnosis were used for this study. These specimens were routinely tested by direct immunofluorescence antigen test, RT-PCR for influenza A and culture for virus isolation as part of routine clinical care. The rapid antigen tests evaluated here (see below) were carried out on the residual specimen left over after routine tests were completed. Fifty-six of the patients were males and 41 were females with an age range of 9 months to 104 years. This study has been approved by the Institutional Review Board of the University of Hong Kong/ Hospital Authority Hong Kong West Cluster.

2.2   RT-PCR for H and M gene of influenza A

The diagnosis of pH1N1 2009 virus, sH1N1 and sH3N2 was performed by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) using primers targeting the hemagglutinin gene of pandemic H1N1 virus according to method described earlier (To et al., 2010, CDC 2007). The quantitation of influenza A virus was performed by using real-time quantitative RT-PCR targeting influenza A virus M gene, as described previously (Li et al., 2010). Briefly, 12 µl of eluted RNA of Influenza A virus was used for cDNA using the Invitrogen Superscript II Kit with a random primer as described, and then, cDNA was amplified in a Lightcycler instrument with a FastStart DNA Master SYBR Green I Mix reagent kit (Roche

74 Diagnostics GmbH, Mannheim, Germany). In a typical reaction, 2 µl of cDNA was amplified in a 20 µl of

75 LC-PCR master mix containing 1X Fast-Start DNA master SYBR green I mix, 4.0 mM $MgCl_2$, 0.5 mM of

76 each primer. To determine the specificity of the assay, all the PCR products were subjected to a melting

77 curve analysis (65–95° C; 0.1^o C per second) at the end of the assay. For quantitative assay, a reference

78 standard was prepared using pCRII-TOPO vector (Invitrogen, San Diego, CA) containing the corresponding

79 target viral sequences. A series of 6 log 10 dilution equivalent to 1 x 10^1 to 1 x 10^6 copies per reaction were

80 prepared to generate calibration curves and run in parallel with the test samples. If the specimen result was

81 outside the upper limit of the expected range, the extract of the sample was repeated with suitable dilution.

82 The detection limit of this assay was 900 copies of RNA per milliliter.

83

84   2.3   Rapid influenza antigen detection kits

85 Four rapid influenza antigen detection kits: QuickVue influenza A+B (Quidel Corpopration, CA, USA);

86 BinaxNow Influenza A+B (Binax, Maine, USA); Directigen EZ Flu A+B (Becton Dickinson and Company,

87 MD, USA); and Epsline influenza A+B ((Fujirebio, Tokyo, Japan) were evaluated. All these tests were

88 carried out according to the manufacturers' instructions (Chan et al., 2009). Briefly, for the QuickVue

89 influenza A + B test, 280 ul of sample was added to the extraction tube containing extraction powder. The

90 extraction tube was swirled gently to dissolve its content. A test strip was placed into the extraction tube. The

91 result was read at 10 minutes. The BinaxNow Influenza A + B test kit used 100 ul of specimen in a virus

92 transport medium to the test device and the result was read after 15 minutes. For the Directigen EZ Flu A +

93   B, 300 µl of sample was mixed with 4 drops of extraction reagent, 3 drops of the mixture was added to the

94   well. The result was read after 15 minutes. The Espline influenza A + B used 40 µl of sample added directly

95   to the well with the result being read after 10 minutes.

96

97   2.4   Viral culture

98   Madin-Darby canine kidney (MDCK) cell monolayers grown in culture tubes were inoculated with 200 µl of

99   sample and incubated at 35°C for 1 hour. The cells were fed with 1 ml of serum-free minimum essential

100   medium containing TPCK (tosylsulfonyl phenylalanylchloromethyl ketone)-treated trypsin (2µg/ml) (Sigma,

101   St. Louis, Mo) and antibiotics (Garamycin, 0.02 mg/ml, Schering-Plough Corporation, Heist-op-den-Berg,

102   Belgium; Penicillin-streptomycin, 100 units/ml, GibcoBRL, NY, USA; Nystatin, 20 units/ml, Sigma, St.

103   Louis, Mo). The cultures were harvested when cytopathic effect (CPE) was observed or after 10 days

104   incubation period for direct immunofluorescent antigen test as described previously (Chan et al., 2008).

105

106   2.5   Direct immunofluorescence antigen test

107   The direct immunofluorescence antigen test was carried out with nasopharyngeal aspirate specimens

108   according to method described previously (Chan et al., 2008). Briefly, the nasopharyngeal aspirate was

109   centrifuged, and the cell pellet was washed in phosphate-buffered saline. The cell pellet was then spotted on

110   6-mm wells of Teflon-coated slides, air dried, and fixed in ice-cold acetone for 10 minutes. The smears were

111   stained with IMAGEN[TM] influenza A and B reagents (Oxoid Limited, Hampshire, UK) and then viewed at a

112　magnification of 400 under epifluorescent illumination using the fluorescein isothiocyanate (FITC) filter of a

113　Nikon fluorescent microscope.

114

115

116　**3.　Results**

117　3.1 Laboratory tests for diagnosis of influenza A infections

118　Ninety-seven nasopharyngeal aspirates collected were tested by RT-PCR for amplification of matrix (M) and

119　subtype-specific hemagglutinin (H) gene assays for diagnosis of influenza A infection. Direct

120　immunofluorescent antigen test and culture were done on all specimens for influenza A. Of these 97

121　influenza A positives, 30, 31 and 36 were identified as pH1N1 2009, sH1N1 and sH3N2 respectively.

122

123　3.2 Rapid influenza antigen detection kits performance

124　The data presented in Table 1 shows that the Directigen EZ Influenza A+B and the Espline Influenza A+B

125　exhibited apparently higher levels of sensitivity for detection of pH1N1 2009 (63.3%), compared with the

126　QuickVue A+B (53.3%) and the BinaxNow (43.3%) but this difference is not statistically significant

127　(Chi-squared test, $p = 0.6$). However, the four RDA tests have the similar levels of sensitivity for detection

128　of sH1N1 (71.0%) or sH3N2 (66.7%-72.2%).

129

130

131   3.3 Viral load of influenza A subtype in nasopharyngeal aspirate

132   The mean of viral load of Influenza A RNA subtype sH3N2 in nasopharyngeal aspirate samples was the

133   highest when compared with influenza A subtype sH1N1 or pH1N1 (Table 2) and these differences were

134   statistically significant (pH1N1 vs sH3N2 p=0.033; pH1N1 vs sH1N1 p=0.047). The limit of detection for

135   each rapid antigen test is defined as the viral load at which $\geq$ 95% of specimens were positive in that test.

136   Therefore the lower limit of viral load detection for each influenza A subtype (pH1N1, sH1N1 and sH3N2

137   by RDA was as follows: the Directigen EZ Influenza A+B (1.1 x 10^7, 4.4 x 10^6 and 1.1 x 10^7); the Espline

138   Influenza A+B (1.1 x 10^7, 4.4 x 10^6 and 1.1 x 10^7); the QuickVue Influenza A+B (1.5 x 10^7, 4.4 x 10^6 and

139   4.5 x 10^6) and the BinaxNOW Influenza A+B (3.5 x 10^7, 4.4 x 10^6 and 4.5 x 10^6) (Fig 1). The average lower

140   limit for detection of each subtype by these rapid antigen assays is pH1N1 (1.8 x 10^7), sH1N1 (4.4 x 10^6)

141   and sH3N2 (7.8 x 10^6) (Table 2).

142

143   3.4 Direct immunofluorescence antigen and culture performance

144   Sensitivity for detection of influenza A subtype by direct immunofluorescence antigen test for sH1N1,

145   pH1N1 and sH3N2 infections was 66.7%, 87.1% and 77.8% respectively (Table 2). Virus isolation from all

146   the samples was attempted on MDCK cells in the presence of TPCK treated trypsin. The isolation rate was

147   similar among the three influenza A subtypes (Table 2).

148

149

4.   Discussion

Previous report showed that these rapid antigen assays had comparable sensitivity to detect pH1N1 and sH1N1 using cell culture grown viruses (Chan et al., 2009). To further understand the analytical sensitivity of these rapid assays in clinical settings, the performance of rapid antigen assays on nasopharyngeal aspirate samples was assessed and compared with viral load by RT-PCR assays. The clinical diagnostic sensitivity of rapid antigen assays for detection of influenza depends on the quality, quantity, site and viral load of clinical specimens used in the assay method as well as its analytical sensitivity (Chan et al., 2007). The sensitivity of all these assays was comparable for the detection of sH1N1and sH3N2 respectively. Any marginal difference in sensitivity between tests may be related to the volume of sample recommended for use in the assay methods. It was reported that larger test volumes gave rise to more sensitive methods (Chan et al., 2007). On the contrary, there was significant variation in the ability of these four assays to detect pH1N1 (Table 1). The Directigen EZ Influenza A+B and the Espline Influenza A+B were the most sensitive among the assays evaluated. These findings are also observed in previous study using culture infected cells (Chan et al., 2009; Hurt et al., 2009).

The influenza A M gene copy number in each clinical sample by RT-PCR have been determined. The highest RNA M gene copy number was found in patients with sH3N2 (2.5 to 5 folds higher) than for patients with sH1N1 or pH1N1 infection. The detection limits of the rapid antigen assays for determination of these subtypes are comparable (Fig. 1). The influenza A subtypes in the sample will generally not be detectable by

169   the rapid antigen assays if the viral load is below 1.0×10^7 copies per ml (Table 2). These clinical derived

170   detection limits are comparable with the detection limits using laboratory culture isolate (Chan et al., 2009).

171

172   The rapid antigen assays were shown to have better performance for the detection of human seasonal

173   influenza A than pH1N1 A in this study. Similarly, the direct immunofluorescence antigen test also shows

174   the highest sensitivity for detection of human seasonal influenza A than pH1N. Since their detection limits

175   for identification of these influenza A subtypes were comparable, the difference in clinical sensitivity is

176   likely to be related to the viral RNA load present in the sample. However, whether there are differences in

177   the affinity of the antibodies used in these different assays that may contribute to these differences in

178   performance cannot be excluded but such differences was not noted in the analytical sensitivity evaluation

179   using cultured virus (Chan et al., 2009).

180

181   Epidemiological and virological studies of the pH1N1 2009 have identified several risk factors for severe

182   infection, including host predisposing factors e.g. extremes of age, chronic underlying diseases, pregnancy,

183   obesity; viral factors and specific mutations of viral proteins such as the D222G mutation in the

184   hemagglutinin (Chen et al., 2010; Lapinsky et al., 2010; Louie et al., 2011). There are also differences in the

185   type of specimen used, with tracheal aspirates giving higher diagnostic yield that nasopharyngeal aspirates in

186   patients who are more seriously ill (Lee et al 2011).

187

188 Rapid point of care antigen detection tests continue to be used for clinical care, especially in out-patient

189 settings and for diagnosing and controlling influenza outbreaks in institutions. It is therefore important to

190 define the clinical diagnostic performance characteristics of these rapid antigen assays. The present studies

191 indicate that the lower clinical sensitivity of rapid antigen assays for pandemic influenza A H1N1 2009

192 infection is associated with lower viral load found in these patients.

193

194

198 **References**

199 Chan KH, Lam SY, Puthavathana P, Nguyen TD, Long HT, Pang CM, Chan KM, Cheung CY, Seto WH,

200 Peiris JS. 2007. Comparative analytical sensitivities of six rapid influenza A antigen detection test kits for

201 detection of influenza A subtypes H1N1, H3N2 and H5N1. J. Clin. Virol. 38, 169-71.

202

203 Chan KH, Peiris JSM, Lim W, Nicholls JM, Chiu SS. 2008. Comparison of nasopharyngeal flocked swabs

204 and aspirates from pediatric patients for rapid diagnosis of respiratory viruses. J. Clin. Virol. 42, 65–69.

205

206 Chan KH, Lai ST, Poon LL, Guan Y, Yuen KY, Peiris JS. 2009. Analytical sensitivity of rapid influenza

207 antigen detection tests for swine-origin influenza virus (H1N1). J. Clin. Virol. 45, 205-7.

208

209 Chen H, Wen X, To KK, Wang P, Tse H, Chan JF, Tsoi HW, Fung KS, Tse CW, Lee RA, Chan KH, Yuen KY.

210 2010. Quasispecies of the D225G substitution in the hemagglutinin of pandemic influenza A(H1N1) 2009

211 virus from patients with severe disease in Hong Kong, China. J. Infect. Dis. 201, 1517-21.

212

213 Centers for Disease Control and Prevention (CDC). 2007. CDC Realtime RT-PCR rRTPCR) protocol for

214 detection and characterization of influenza (version 2007). CDC REF. # I-007-05.

215

216 Cowling BJ, Chan KH, Fang VJ, Lau LL, So HC, Fung RO, Ma ES, Kwong AS, Chan CW, Tsui WW, Ngai

217 HY, Chu DW, Lee PW, Chiu MC, Leung GM, Peiris JS. 2010. Comparative epidemiology of pandemic and

218 seasonal influenza A in households. N. Engl. J. Med. 362, 2175-84.

219

220 de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, Hoang DM, Van Vinh Chau N,

221 Khanh TH, Dong VC, Qui PT, Van Cam B, Ha DQ, Guan Y, Peiris JS, Chinh NT, Hien TT, Farrar J. 2006.

222 Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat.

223 Med. 12,1203–7.

224

225 Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, Hollingsworth TD, Griffin J,

226 Baggaley RF, Jenkins HE, Lyons EJ, Jombart T, Hinsley WR, Grassly NC, Balloux F, Ghani AC, Ferguson

227 NM, Rambaut A, Pybus OG, Lopez-Gatell H, Alpuche-Aranda CM, Chapela IB, Zavala EP, Guevara DM,

228 Checchi F, Garcia E, Hugonnet S, Roth C. 2009. WHO Rapid Pandemic Assessment Collaboration.

229 Pandemic potential of a strain of influenza A (H1N1): early findings. Science 324, 1557-61.

230

231 Ginocchio CC, Zhang F, Manji R, Arora S, Bornfreund M, Falk L, Lotlikar M, Kowerska M, Becker G,

232 Korologos D, de Geronimo M, Crawford JM. 2009. Evaluation of multiple test methods for the detection of

233 the novel 2009 influenza A (H1N1) during the New York City outbreak. J. Clin. Virol. 45, 191-195.

234

235   Gordon A, Videa E, Saborio S, Lopez R, Kuan G, Balmaseda A, Harris E. 2010. Diagnostic accuracy of a

236   rapid influenza test for pandemic influenza A H1N1. PLoS One 5: e10364.

237

238   Hurt AC, Baas C, Deng YM, Roberts S, Kelso A, Barr IG. 2009. Performance of influenza rapid

239   point-of-care tests in the detection of swine lineage A (H1N1) influenza viruses. Influenza Other Respi.

240   Viruses 3,171-6.

241

242   Kumar B, Sharma B, Khanna M, Singh V, Daga MK, Vijayan VK, Mishra AC, Chadha MS, Chawla-Sarkar

243   M and Kaur H. 2010. Comparison of various immunoassay kits for rapid screening of pandemic influenza

244   H1N1-2009 viruses. J. Public Health and Epidemiol. 2, 175-179.

245

246   Lapinsky SE. 2010. Critical illness as a result of influenza A/H1N1 infection in pregnancy. B.M.J.

247   340:c1235.

248

249   Lee N, Chan PK, Wong CK, Wong KT, Choi KW, Joynt GM, Lam P, Chan MC, Wong BC, Lui GC, Sin

250   WW, Wong RY, Lam WY, Yeung AC, Leung TF, So HY, Yu AW, Sung JJ, Hui DS. 2011. Viral clearance and

251   inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A (H1N1) virus

252   pneumonia. Antivir. Ther. 16, 237-47.

253   Li IW, Hung IF, To KK, Chan KH, Wong SS, Chan JF, Cheng VC, Tsang OT, Lai ST, Lau YL, Yuen KY.

254 2010. The natural viral load profile of patients with pandemic swine-origin influenza A H1N1 2009 (pH1N1)

255 and the effect of oseltamivir treatment. Chest 137, 759-68.

256

257 Louie JK, Acosta M, Samuel MC Schechter R, Vugia DJ, Harriman K, Matyas BT; California Pandemic

258 (H1N1) Working Group. 2011. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A

259 (H1N1). Clin. Infect. Dis. 52, 301-12.

260

261 To KK, Wong SS, Li IW, Hung IF, Tse H, Woo PC, Chan KH, Yuen KY. 2010. Concurrent comparison of

262 epidemiology, clinical presentation and outcome between adult patients suffering from the pandemic

263 influenza A (H1N1) 2009 virus and the seasonal influenza A virus infection. Postgrad. Med. J. 86,515-21.

264

265 Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. 2009. Emergence of a Novel

266 Swine-Origin Influenza A (H1N1) Virus in Humans. N. Engl. J. Med. 360, 2605-2615

267

268 Yang JR, Lo J, Ho YL, Wu HS, Liu MT. 2011. Pandemic H1N1 and seasonal H3N2 influenza infection in

269 the human population show different distributions of viral loads, which substantially affect the performance

270 of rapid influenza tests. Virus Res. 155, 163-7.

271

Legend

273 Table 1 Performance of the four rapid antigen assays for detection of different influenza A subtypes

274

275 Table 2 Compare different methods for diagnosis of influenza infections

276

277 Fig. 1 Viral RNA M gene copy number present in patient with pH1N1, sH1N1 and sH3N2 are denoted

278 together with the rapid antigen test results for each test kit. The limit of detection for each rapid antigen test

279 is denoted by a horizontal line as the viral load at which $\geq 95\%$ of specimens were positive in that test.

280

281   Table 1 Performance of the four rapid antigen assays for detection of different influenza A subtypes

282

Influenza A subtypes (No. of patients)	BinaxNOW Influenza A+B	QuickVue Influenza A+B	Directigen EZ Influenza A+B	Espline Influenza A+B
pH1N1 2009 = 30	43.3%	53.3%	63.3%	63.3%
sH1N1 =31	71.0%	71.0%	71.0%	71.0%
sH3N2 =36	66.7%	72.2%	69.4%	69.4%

283

284

285   Table 2   Compare different methods for diagnosis of influenza infections

286

Influenza A subtype = No. of patients	Mean of viral load (copies/ml) (Range)	IF	Culture	Rapid detection assays Mean of (Detection limit)
pH1N1 2009 =30	1.83×10^8 (6.37×10^2 - 2.00×10^9)	66.7%	96.7%	55.8% (1.8×10^7)
sH1N1 =31	3.89×10^8 (5.40×10^4 - 3.40×10^{10})	87.1%	97.0%	71.0% (4.4×10^6)
sH3N2 =36	9.63×10^8 (2.34×10^4 - 1.17×10^{10})	77.8%	97.2%	69.4% (7.8×10^6)
Overall Mean	5.12E+08	77.2%	97.0%	65.4% (1.0×10^7)

287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

| Influenza A subtype	Mean of viral load	IF	Culture	Rapid detection assays

321 Fig. 1 Viral RNA M gene copy number present in patient with pH1N1, sH1N1 and sH3N2 are denoted

322 together with the rapid antigen test results for each test kit. The limit of detection for each rapid antigen test

323 is denoted by a horizontal line as the viral load at which ≥ 95% of specimens were positive in that test.

324

325 (a)   (b)

326

327 (b)   (d)

328

329 ———— : Detection limit

330 ● Positive

331 o Negative

332